Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 591

1.

SNW1 is a prognostic biomarker in prostate cancer.

Höflmayer D, Willich C, Hube-Magg C, Simon R, Lang D, Neubauer E, Jacobsen F, Hinsch A, Luebke AM, Tsourlakis MC, Huland H, Graefen M, Haese A, Heinzer H, Minner S, Büscheck F, Sauter G, Schlomm T, Steurer S, Clauditz TS, Burandt E, Wilczak W, Bernreuther C.

Diagn Pathol. 2019 May 1;14(1):33. doi: 10.1186/s13000-019-0810-8.

2.

A nuclear shift of GSK3β protein is an independent prognostic factor in prostate cancer.

Eichenauer T, Hussein M, Hube-Magg C, Kluth M, Büscheck F, Höflmayer D, Tsourlakis MC, Steurer S, Clauditz TS, Luebke AM, Burandt E, Wilczak W, Hinsch A, Dum D, Beyer B, Steuber T, Huland H, Graefen M, Simon R, Sauter G, Melling N, Schlomm T, Minner S.

Oncotarget. 2019 Mar 1;10(18):1729-1744. doi: 10.18632/oncotarget.26739. eCollection 2019 Mar 1.

3.

p53 overexpression is a prognosticator of poor outcome in esophageal cancer.

Melling N, Norrenbrock S, Kluth M, Simon R, Hube-Magg C, Steurer S, Hinsch A, Burandt E, Jacobsen F, Wilczak W, Quaas A, Bockhorn M, Grupp K, Tachezy M, Izbicki J, Sauter G, Gebauer F.

Oncol Lett. 2019 Apr;17(4):3826-3834. doi: 10.3892/ol.2019.10020. Epub 2019 Feb 6.

4.

The impact of variant histological differentiation on extranodal extension and survival in node positive bladder cancer treated with radical cystectomy.

Marks P, Gild P, Soave A, Janisch F, Minner S, Engel O, Vetterlein MW, Shariat SF, Sauter G, Dahlem R, Fisch M, Rink M.

Surg Oncol. 2019 Mar;28:208-213. doi: 10.1016/j.suronc.2019.01.008. Epub 2019 Jan 30.

PMID:
30851902
5.

Increase of CD45-positive Immune Cells in Liver Parenchyma Indicates a More Favorable Prognosis for Patients With Barrett's Cancer.

Kemper M, Strohm T, Grupp K, Ghadban T, Bogoevski D, Bachmann K, Bockhorn M, Sauter G, Izbicki JR, Reeh M.

Anticancer Res. 2019 Mar;39(3):1191-1196. doi: 10.21873/anticanres.13229.

PMID:
30842149
6.

Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance.

Horak P, Weischenfeldt J, von Amsberg G, Beyer B, Schütte A, Uhrig S, Gieldon L, Klink B, Feuerbach L, Hübschmann D, Kreutzfeldt S, Heining C, Maier S, Hutter B, Penzel R, Schlesner M, Eils R, Sauter G, Stenzinger A, Brors B, Schröck E, Glimm H, Fröhling S, Schlomm T.

Cold Spring Harb Mol Case Stud. 2019 Apr 1;5(2). pii: a003657. doi: 10.1101/mcs.a003657. Print 2019 Apr.

7.

Current Therapies of Wilms Tumors in the Adult: Diagnostic Considerations and Treatment Challenges.

Bradtke M, Rink M, Büscheck F, Sauter G, Dahlem R, Fisch M, Vetterlein MW.

Clin Genitourin Cancer. 2019 Feb 5. pii: S1558-7673(19)30042-4. doi: 10.1016/j.clgc.2019.01.016. [Epub ahead of print] No abstract available.

PMID:
30833124
8.

Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer.

Schroeder C, Grell J, Hube-Magg C, Kluth M, Lang D, Simon R, Höflmayer D, Minner S, Burandt E, Clauditz TS, Büscheck F, Jacobsen F, Huland H, Graefen M, Schlomm T, Sauter G, Steurer S.

BMC Cancer. 2019 Mar 1;19(1):193. doi: 10.1186/s12885-019-5390-1.

9.

Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer.

Blessin NC, Simon R, Kluth M, Fischer K, Hube-Magg C, Li W, Makrypidi-Fraune G, Wellge B, Mandelkow T, Debatin NF, Höflmayer D, Lennartz M, Sauter G, Izbicki JR, Minner S, Büscheck F, Uhlig R, Dum D, Krech T, Luebke AM, Wittmer C, Jacobsen F, Burandt EC, Steurer S, Wilczak W, Hinsch A.

Dis Markers. 2019 Jan 10;2019:5160565. doi: 10.1155/2019/5160565. eCollection 2019.

10.

Deep Learning for Natural Language Processing in Urology: State-of-the-Art Automated Extraction of Detailed Pathologic Prostate Cancer Data From Narratively Written Electronic Health Records.

Leyh-Bannurah SR, Tian Z, Karakiewicz PI, Wolffgang U, Sauter G, Fisch M, Pehrke D, Huland H, Graefen M, Budäus L.

JCO Clin Cancer Inform. 2018 Dec;2:1-9. doi: 10.1200/CCI.18.00080.

11.

5q21 deletion is often heterogeneous in prostate cancer.

Kluth M, Al Kilani Z, Özden C, Hussein K, Frogh S, Möller-Koop C, Burandt E, Steurer S, Büscheck F, Jacobsen F, Luebke AM, Minner S, Tsourlakis MC, Hoeflmayer D, Wittmer C, Schlomm T, Sauter G, Simon R, Wilczak W.

Genes Chromosomes Cancer. 2019 Jan 9. doi: 10.1002/gcc.22730. [Epub ahead of print]

PMID:
30623509
12.

High expression of class III β-tubulin in upper gastrointestinal cancer types.

Höflmayer D, Öztürk E, Schroeder C, Hube-Magg C, Blessin NC, Simon R, Lang DS, Neubauer E, Göbel C, Heinrich MC, Fraune C, Möller K, Armbrust M, Freytag M, Hinsch A, Lühr C, Noack M, Reiswich V, Weidemann S, Bockhorn M, Perez D, Izbicki JR, Sauter G, Jacobsen F.

Oncol Lett. 2018 Dec;16(6):7139-7145. doi: 10.3892/ol.2018.9502. Epub 2018 Sep 25.

13.

Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.

Gerhauser C, Favero F, Risch T, Simon R, Feuerbach L, Assenov Y, Heckmann D, Sidiropoulos N, Waszak SM, Hübschmann D, Urbanucci A, Girma EG, Kuryshev V, Klimczak LJ, Saini N, Stütz AM, Weichenhan D, Böttcher LM, Toth R, Hendriksen JD, Koop C, Lutsik P, Matzk S, Warnatz HJ, Amstislavskiy V, Feuerstein C, Raeder B, Bogatyrova O, Schmitz EM, Hube-Magg C, Kluth M, Huland H, Graefen M, Lawerenz C, Henry GH, Yamaguchi TN, Malewska A, Meiners J, Schilling D, Reisinger E, Eils R, Schlesner M, Strand DW, Bristow RG, Boutros PC, von Kalle C, Gordenin D, Sültmann H, Brors B, Sauter G, Plass C, Yaspo ML, Korbel JO, Schlomm T, Weischenfeldt J.

Cancer Cell. 2018 Dec 10;34(6):996-1011.e8. doi: 10.1016/j.ccell.2018.10.016.

PMID:
30537516
14.

Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines.

Press MF, Seoane JA, Curtis C, Quinaux E, Guzman R, Sauter G, Eiermann W, Mackey JR, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Bee V, Ma Y, Villalobos I, Slamon DJ.

JAMA Oncol. 2019 Mar 1;5(3):366-375. doi: 10.1001/jamaoncol.2018.6012.

15.

Upregulation of centromere protein F is linked to aggressive prostate cancers.

Göbel C, Özden C, Schroeder C, Hube-Magg C, Kluth M, Möller-Koop C, Neubauer E, Hinsch A, Jacobsen F, Simon R, Sauter G, Michl U, Pehrke D, Huland H, Graefen M, Schlomm T, Luebke AM.

Cancer Manag Res. 2018 Nov 9;10:5491-5504. doi: 10.2147/CMAR.S165630. eCollection 2018.

16.

Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma.

Li W, Blessin NC, Simon R, Kluth M, Fischer K, Hube-Magg C, Makrypidi-Fraune G, Wellge B, Mandelkow T, Debatin NF, Pott L, Höflmayer D, Lennartz M, Sauter G, Izbicki JR, Minner S, Büscheck F, Uhlig R, Dum D, Krech T, Luebke AM, Wittmer C, Jacobsen F, Burandt E, Steurer S, Wilczak W, Hinsch A.

BMC Cancer. 2018 Dec 4;18(1):1209. doi: 10.1186/s12885-018-5111-1.

17.

Deletion of 3p13 is a late event linked to progression of TMPRSS2:ERG fusion prostate cancer.

Kluth M, Volta H, Hussein M, Taskin B, Frogh S, Möller-Koop C, Büscheck F, Jacobsen F, Tsourlakis MC, Lübke AM, Hinsch A, Clauditz T, Graefen M, Heinzer H, Huland H, Minner S, Sauter G, Wilczak W, Schlomm T, Simon R.

Cancer Manag Res. 2018 Nov 19;10:5909-5917. doi: 10.2147/CMAR.S172637. eCollection 2018.

18.

Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers.

Minner S, Lutz J, Hube-Magg C, Kluth M, Simon R, Höflmayer D, Burandt E, Tsourlakis MC, Sauter G, Büscheck F, Wilczak W, Steurer S, Schlomm T, Huland H, Graefen M, Haese A, Heinzer H, Jacobsen F, Hinsch A, Poos A, Oswald M, Rippe K, König R, Schroeder C.

Prostate. 2019 Feb;79(3):302-311. doi: 10.1002/pros.23736. Epub 2018 Nov 14.

PMID:
30430607
19.

Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcome.

Grupp K, Hofmann B, Kutup A, Bachmann K, Bogoevski D, Melling N, Uzunoglu FG, El Gammal AT, Koop C, Simon R, Steurer S, Krech T, Burdak-Rothkamm S, Jacobsen F, Sauter G, Izbicki J, Wilczak W.

BMC Cancer. 2018 Nov 12;18(1):1106. doi: 10.1186/s12885-018-5032-z.

20.

Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma.

Büscheck F, Fraune C, Simon R, Kluth M, Hube-Magg C, Möller-Koop C, Shadanpour N, Bannenberg C, Eichelberg C, Höflmayer D, Clauditz T, Wittmer C, Wilczak W, Sauter G, Fisch M, Rink M, Eichenauer T.

Urol Oncol. 2018 Dec;36(12):531.e19-531.e25. doi: 10.1016/j.urolonc.2018.08.015. Epub 2018 Oct 12.

PMID:
30322727

Supplemental Content

Loading ...
Support Center